Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Annual EBITDA margin expands by 170 basis points
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Subscribe To Our Newsletter & Stay Updated
